U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT07494396) titled 'An AI-Based Erythema Measurement System for Psoriasis Lesions' on March 20.
Brief Summary: Psoriasis is a common chronic inflammatory skin disease. Disease severity is commonly assessed using the Psoriasis Area and Severity Index (PASI), in which erythema is graded subjectively on a 0-4 scale. This visual assessment is prone to significant inter- and intra-rater variability.
Although objective tools such as colorimeters provide accurate erythema measurement, their high cost limits routine clinical use. Smartphone imaging combined with artificial intelligence (AI) offers a practical alternative for objective assessment. However, va...